KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) EPS (Basic): 2009-2025

Historic EPS (Basic) for Biomarin Pharmaceutical (BMRN) over the last 14 years, with Sep 2025 value amounting to -$0.16.

  • Biomarin Pharmaceutical's EPS (Basic) fell 128.57% to -$0.16 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.72, marking a year-over-year increase of 60.00%. This contributed to the annual value of $2.25 for FY2024, which is 152.81% up from last year.
  • According to the latest figures from Q3 2025, Biomarin Pharmaceutical's EPS (Basic) is -$0.16, which was down 112.80% from $1.25 recorded in Q2 2025.
  • Over the past 5 years, Biomarin Pharmaceutical's EPS (Basic) peaked at $1.25 during Q2 2025, and registered a low of -$0.32 during Q4 2021.
  • For the 3-year period, Biomarin Pharmaceutical's EPS (Basic) averaged around $0.47, with its median value being $0.47 (2024).
  • In the last 5 years, Biomarin Pharmaceutical's EPS (Basic) crashed by 455.56% in 2021 and then skyrocketed by 1,200.00% in 2023.
  • Quarterly analysis of 5 years shows Biomarin Pharmaceutical's EPS (Basic) stood at -$0.32 in 2021, then skyrocketed by 96.88% to -$0.01 in 2022, then spiked by 1,200.00% to $0.11 in 2023, then surged by 500.00% to $0.66 in 2024, then crashed by 128.57% to -$0.16 in 2025.
  • Its last three reported values are -$0.16 in Q3 2025, $1.25 for Q2 2025, and $0.97 during Q1 2025.